Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen
Sponsors
Novo Nordisk A/S, Trinity College Dublin, Clinical Pharmacology, Department of, Kailera Therapeutics Inc.
Conditions
AdipositasCardiovascular disorders: Hypertension and ObesityObesityObesity and overweightParticipants with overweight or obesityand type 2 diabetes
Phase 3
Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight
Active, not recruitingCTIS2022-502922-41-00
Start: 2023-07-03Target: 86Updated: 2025-11-03
Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.
RecruitingCTIS2024-513958-29-00
Start: 2025-04-24Target: 50Updated: 2025-11-10
A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes
Not yet recruitingCTIS2025-523511-11-00
Target: 126Updated: 2026-04-29
Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)
Not yet recruitingCTIS2024-520446-31-00
Target: 85Updated: 2026-05-15
Phase 4
Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly
Active, not recruitingCTIS2023-508055-40-00
Start: 2025-02-18Target: 309Updated: 2025-12-14
The GOAL study: GLP-1 receptor agonist treatment for Adolescents with Obesity secondary to Antipsychotic Medication - A feasibility study
RecruitingCTIS2024-517471-21-02
Start: 2025-06-24Target: 34Updated: 2025-05-02